ghk cu clinical studies GHK-Cu for Skin: What the Evidence Shows ghk cu human clinical trials

It does not constitute dosing advice, clinical guidance, or a recommendation for human or veterinary application

doi:10.1177/106002809502907-823

published in Journal of Pharmacology and Experimental Therapeutics used daily subcutaneous injections at 0.1 mg/kg in scopolamine-induced amnesia models in rats

Because it degrades in blood in a pathway involving amino-peptidases, it may not be suitable for people who take medications that inhibit or are metabolized by peptidases (e.g., captopril, a treatment for hypertension).4 Also, based on what we know about other therapeutic peptides, we would say DSIP is contraindicated for women who are pregnant or breastfeeding as well as people with a personal history of cancer

Intracellular Target Access The compound was able to enter the cell models used in the foundational study and reduce the intracellular target-engagement marker 1-methylnicotinamide